Table 3.

Percentage Change in HDL Function Marker by Covariate in Multivariate Repeated Measures Analysis-CRP models.

	HII		PON1 Activity		HDL-Hp		HDL-ApoAI		MPO
	Effects	p	Effects	P	Effects	p	Effects	P	Effects	p
CRP (per 10 unit decrease)	−2.34%	<0.01	3.42%	<0.01	−3.53%	<0.01	8.74%	<0.01	−1.91%	0.07
Treatment (overall)		0.05		0.63		0.07		0.30		0.49
MTX +ETA vs TT	9.69%	0.07	2.97%	0.68	10.63%	0.02	−18.88%	0.21	−3.93%	0.46
MTX +ETA vs MTX	−3.23%	0.44	−4.11%	0.51	3.72%	0.36	5.66%	0.70	3.32%	0.53
TT vs MTX	−11.78%	0.02	−6.87%	0.35	−6.24%	0.18	30.25%	0.13	7.55%	0.23
Race (overall)		0.05		<0.01		0.03		0.21		<0.01
AA vs Caucasian	−18.53%	0.03	45.64%	<0.01	−13.82%	0.05	56.88%	0.13	37.64%	<0.01
AA vs Others	−25.27%	0.02	14.90%	0.39	−22.74%	0.01	98.60%	0.09	12.84%	0.30
Others vs Caucasian	9.03%	0.36	26.76%	0.05	11.55%	0.14	−21.01%	0.43	21.98%	0.02
BMI (per unit increase)	1.19%	<0.01	−0.31%	0.51	0.74%	0.01	−2.79%	0.02	−0.17%	0.61
Age (per year increase)	−0.03%	0.89	0.24%	0.41	−0.08%	0.64	0.85%	0.25	−0.22%	0.31
Female vs Male	−7.91%	0.18	7.17%	0.37	−0.52%	0.91	0.99%	0.96	−15.09%	<0.01
Disease Duration (per year increase)	0.59%	0.15	−0.03%	0.95	0.06%	0.86	0.23%	0.86	−0.94%	0.01
Baseline Smoking: Yes vs No	10.34%	0.09	0.43%	0.95	0.28%	0.95	−30.94%	0.05	5.41%	0.32
Baseline Prednisone Use: Yes vs No	2.34%	0.67	10.93%	0.13	6.96%	0.11	34.47%	0.08	8.00%	0.12
Baseline Statin Use: Yes vs No	−11.63%	0.15	−5.29%	0.62	4.77%	0.49	34.54%	0.28	−6.05%	0.43
Baseline Cardiovascular Disease: Yes vs No	10.31%	0.46	−20.08%	0.19	−13.64%	0.16	10.80%	0.81	−8.10%	0.49
Baseline Diabetes Status: Yes vs No	−15.19%	0.08	−6.92%	0.55	−11.52%	0.10	−6.76%	0.83	−1.44%	0.87

Percentage change in HDL function variables are shown per categorical variable or per unit change in continuous variables as specified. CRP= C-reactive protein. TT= triple therapy. MTX= methotrexate. ETA= etanercept. AA = African American. BMI= body mass index.